This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-07 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
== Origin == In 2026, Androgenic, an Australian looksmaxxing influencer, revealed the "pentastack", a list of five substances which he uses while livestreaming. Adderall, Dextromethorphan and Ketamine are fairly common off-the-shelf pharmaceuticals with legitimate medical use. Pregabalin (under the brand name Lyrica) is a drug used to treat epilepsy and other nervous damages, and has sedative effects. 1,4-Butanediol (with street names like "Bute", "One Comma Four" or "Liquid Fantasy") is a chemical that exerts similar euphoric effects to its metabolite, GABA analogue gamma-hydroxybutyrate (GHB). BDO can cause seizures, nausea, vomiting, and withdrawal symptoms can potentially cause death.
East Germany closed itself to the sporting world in May 1965. In 1977 the shot-putter Ilona Slupianek, who weighed 93 kg, failed a test for anabolic steroids at the European Cup meeting in Helsinki and thereafter athletes were tested before they left the country. At the same time, the Kreischa testing laboratory near Dresden passed into government control; it reputedly made around 12,000 tests a year on East German athletes but without any being penalised. The International Amateur Athletics Federation (IAAF) suspended Slupianek for 12 months, a penalty that ended two days before the European championships in Prague. In the reverse of what the IAAF hoped, sending her home to East Germany meant she was free to train unchecked with anabolic steroids, if she wanted to, and then compete for another gold medal, which she won. After that, almost nothing emerged from the East German sports schools and laboratories. A rare exception was the visit by the sports-writer and former athlete, Doug Gilbert of the Edmonton Sun, who said:
Dual diagnosis (also called co-occurring disorders (COD) or dual pathology) is the condition of having a mental illness and a comorbid substance use disorder. There is considerable debate surrounding the appropriateness of using a single category for a heterogeneous group of individuals with complex needs and a varied range of problems. The concept can be used broadly, for example depression and alcohol use disorder, or it can be restricted to specify severe mental illness (e.g. psychosis, schizophrenia) and substance use disorder (e.g. cannabis use), or a person who has a milder mental illness and a drug dependency, such as panic disorder or generalized anxiety disorder and is dependent on opioids. Diagnosing a primary psychiatric illness in people who use substances is challenging as substance use disorder itself often induces psychiatric symptoms, thus making it necessary to differentiate between substance induced and pre-existing mental illness. Those with co-occurring disorders face complex challenges. They have increased rates of relapse, hospitalization, homelessness, and HIV and hepatitis C infection compared to those with either mental or substance use disorders alone.
Sources: en.wikipedia.org
The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to target and destroy them. Scientists harvest T cells from people, genetically alter them to add a chimeric antigen receptor (CAR) that specifically recognizes cancer cells, then infuse the resulting CAR-T cells into patients to attack their tumors. Tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR-T) therapy, was approved by the FDA in 2017 to treat acute lymphoblastic leukemia (ALL). This treatment removes CD19 positive cells (B-cells) from the body (including the diseased cells, but also normal antibody-producing cells). Axicabtagene ciloleucel (Yescarta) is another CAR-T therapeutic, approved in 2017 for treatment of diffuse large B-cell lymphoma (DLBCL).
==== Moisture content differences ==== The chemical potential is explained here since it is the true driving force for the transport of water in both liquid and vapour phases in wood. The Gibbs free energy per mole of substance is usually expressed as the chemical potential of that substance. The chemical potential of water in unsaturated air or wood below the fibre saturation point influences the drying of wood. Equilibrium will occur at the equilibrium moisture content (as defined earlier) of wood when the chemical potential of water in the wood becomes equal to that in the surrounding air. The chemical potential of sorbed water is a function of wood moisture content. Therefore, a gradient of wood moisture content (between surface and centre), or more specifically of water activity, is accompanied by a gradient of chemical potential under isothermal conditions. Moisture will redistribute itself throughout the wood until its chemical potential is uniform throughout, resulting in a zero potential gradient at equilibrium. The flux of moisture attempting to achieve the equilibrium state is assumed to be proportional to the difference in its chemical potential, and inversely proportional to the path length over which the potential difference acts. The gradient in chemical potential is related to the moisture content gradient as explained in above equations. The diffusion model using the moisture content gradient as a driving force was applied successfully by Wu (1989) and Doe et al. (1994).
The former maintains its own border control policies, thus requiring physical border security at its border with the Schengen Area, as well as implementing border controls for travellers travelling directly between Gibraltar and the British mainland. The latter maintains a relatively open border with Southern Cyprus, though not with Northern Cyprus. Consequently, it is a de facto member of the Schengen Area, and travel to or from the British mainland is subject to border controls. On 31 December 2020, Spain and the United Kingdom reached an agreement in principle under which Gibraltar would join the Schengen Area, clearing the way for the European Union and the UK to start formal negotiations on the matter. In the aftermath of Brexit, border controls for goods flowing between Great Britain and Northern Ireland were introduced in accordance with the Protocol on Ireland/Northern Ireland agreed to as part of the UK's withdrawal agreement with the EU. Due to the thirty-year internecine conflict in Northern Ireland, the UK-Ireland border has had a special status since that conflict was ended by the Belfast Agreement/Good Friday Agreement of 1998. As part of the Northern Ireland Peace Process, the border has been largely invisible, without any physical barrier or custom checks on its many crossing points; this arrangement was made possible by both countries' common membership of both the EU's Single Market and Customs Union and of their Common Travel Area.
Sources: en.wikipedia.org
Typically, the complete breakdown of one molecule of glucose by aerobic respiration (i.e. involving glycolysis, the citric-acid cycle and oxidative phosphorylation, the last providing the most energy) is usually about 30–32 molecules of ATP. Oxidation of one gram of carbohydrate yields approximately 4 kcal of energy.
"Catholic conservatives in the Weimar Republic: the politics of the Rhenish-Westphalian aristocracy, 1918–1933." German History 18.1 (2000): 60-85. Kohler, Eric D. "The Successful German Center-Left: Joseph Hess and the Prussian Center Party, 1908–32." Central European History 23.4 (1990): 313-348. Lutz, Ralph Haswell. "The Collapse of German Democracy under the Brüning Government March 30, 1930–May 30, 1932." Pacific Historical Review (1941) 10#1: 1-14. online Ross, Ronald J. "Critic of the Bismarckian Constitution: Ludwig Windthorst and the Relationship Between Church and State in Imperial Germany," Journal of Church & State (1979) 21#3 pp 483–506. online Ross, Ronald J. Beleaguered Tower: The Dilemma of Political Catholicism in Wilhelmine Germany (1976), Zeender, John. "Ludwig Windthorst, 1812-1891," History (1992) 77#290 pp 237–54 online Zeender, John K. "The German Center Party, 1890-1906." Transactions of the American Philosophical Society (1976) 66#1 pp 1–125.
The organic compound citrulline is a non-essential α-amino acid. Its name is derived from citrullus, the Latin word for watermelon. Although named and described by gastroenterologists since the late 19th century, it was first isolated from watermelon in 1914 by Japanese researchers Yatarō Koga and Ryō Ōtake, and further codified in 1930. Citrulline has the formula H2NC(O)NH(CH2)3CH(NH2)CO2H. It is a key intermediate in the urea cycle, the pathway by which mammals excrete ammonia by converting it into urea. Citrulline is also produced as a byproduct of the enzymatic production of nitric oxide from the amino acid arginine, catalyzed by nitric oxide synthase.
In microorganisms and plants, the enzyme serine acetyltransferase catalyzes the transfer of acetyl group from acetyl-CoA onto L-serine to yield O-acetyl-L-serine. The following reaction step, catalyzed by the enzyme O-acetyl serine (thiol) lyase, replaces the acetyl group of O-acetyl-L-serine with sulfide to yield cysteine.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.